Atorvastatin
- Atc Codes:C10AA05
- CAS Codes:134523-03-8#134523-00-5
- PHARMGKB ID:134523-03-8#134523-00-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Atocornex, Atofloc, Atolipidrin, Atolux, Atorvastatin, Callator, Sortis; Belgium: Lipitor; Bulgaria: Atoris, Sortis, Torvacard, Tulip; Cyprus: Atacor, Lipitor; Czech Republic: Atoris, Atorpharm, Atorvastatin, Bisatum, Larus, Pharmtina, Sortis, Torvacard, Torvazin, Triglyx, Tulip, Vaston, Voredanin, Xippatin; Denmark: Lipitor, Tahor, Torvast, Zarator; Estonia: Atilen, Atoris, Atorvastatin, Lopamol, Sortis, Torvacard; Finland: Atorvastatin, Lipitor; France: Tahor; Germany: Aterfinar, Atorvastatin, Atorvatapina, Atorvazetor, Atorvelden, Ferolastatin, Lipitor, Liprimar, Sortis; Greece: Altoram, Antorcin, Arvastatil, Ator-Chol, Atorgon, Atorlip, Atorstat, Atorval, Atorvalet, Atorvanox, Atorvastatin, Atorvin, Atrost, Atrosterol, Atrovita, Biger, Card-OK, Danelip, Delipost, Edovin, Fluxol, Holisten, Lipigan, Lipitor, Lipium-Raldex, Lipizem, Lipodial, Lipostatin, Lipovast, Lorvaten, Rotova, Torvaplus, Torvastin, Vastazor, Xanator, Zarator; Hungary: Atoris, Atorva, Atorvastatin, Atorvox, Copator, Decholest, Dislipat, Engolin, Hypolip, Liprimar, Lopamol, Pharmastatin, Sortis, Torvacard, Torvalipin, Voredanin; Ireland: Lipitor; Italy: Lipitor, Torvast, Totalip, Xarator; Latvia: Atilen, Atoris, Atorvastatin, Lopamol, Sortis, Torvacard, Tulip; Lithuania: Abaran, Atilen, Atoris, Atorvastatin, Lopamol, Sortis, Torvacard, Tulip; Malta: Atacor, Atorvastatin, Lipitor; Netherlands: Atorvastatine, Lipitor, Sortis; Poland: Atoris, Atorvastatin, Atorvasterol, Atorvox, Atractin, Atrox, Corator, Larus, Sortis, Torvacard, Torvalipin, Torvazin, Tulip, Voredanin, Xavitor; Portugal: Atorvastatina, Minilip, Texzor, Zarator; Romania: Atoris, Atorvastatina, Pharmastatin, Sortis, Torvacard, Torvalipin, Voredanin; Slovakia: Atilen, Atoris, Atorvastatin, Gletor, Larus, Pharmastatin, Sortis, Spatizalex, Torvacard, Tulip, Voredanin; Slovenia: Atoris, Sortis, Torvalipin, Tulip; Spain: Atorvastatina, Cardyl, Prevencor, Zarator; Sweden: Atorvastatin, Atostin, Atovans, Lipitor, Sortis, Tahor, Torvast, Zarator; UK: Lipitor.
North America
Canada: Lipitor; USA: Lipitor.
Latin America
Argentina: Ampliar, Atarva, Ateroclar-Beta, Atorvastan, Atorvastatin, Atorvastatina, Faboxim, Finlipol, Liparex, Lipibec, Lipifen, Lipitor, Lipocambi, Lipofin, Liponorm-Lazar, Lipostop, Lipovastatin, Normalip, Plan, Sincol-Indeco, Tialipol, Torivas, Trimstat, Vanator, Vastina, Zarator; Brazil: Citalor, Lípitor; Mexico: Lipitor.
Asia
Japan: Lipitor.
Drug combinations
Atorvastatin and Amlodipine
Atorvastatin and Ezetimibe
Chemistry
Atorvastatin Calcium: C~66~H~68~CaF~2~N~4~O~10~. Mw: 1155.34. (1) 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), [R-(R*,R*)]-; (2) Calcium (βR,δR)-2-(p-fluorophenyl)-β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2). CAS-134523-03-8; CAS-134523-00-5 (atorvastatin)(1994).
Pharmacologic Category
Antilipemic Agents; HMG-CoA Reductase Inhibitors. (ATC-Code: C10AA05).
Mechanism of action
Inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, resulting in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism.
Therapeutic use
Treatment of dyslipidemias or primary prevention of cardiovascular disease (atherosclerotic).
Pregnancy and lactiation implications
Contraindicated during pregnancy and lactation. Administer to women of childbearing potential only when conception is highly unlikely.
Unlabeled use
Contraindications
Hypersensitivity to atorvastatin or any component of the formulation. Active liver disease. Unexplained persistent elevations of serum transaminases. Pregnancy.
Warnings and precautions
Rhabdomyolysis with acute renal failure and/or myopathy may develop with use (risk is dose-related and increased with concurrent use of CYP3A4 inhibitors (e.g. CSA, clarithromycin, protease inhibitors), fibric acid derivatives (e.g. gemfibrozil), or niacin). Patients with history of hemorrhagic stroke may be at increased risk for another. Hepatic impairment (use with caution in patients who consume large amounts of ethanol or have history of liver disease). CYP-mediated interactions (use with caution in patients taking strong CYP3A4 inhibitors). Use with caution in the elderly (predisposed to myopathy).